Biochip and detection method for detecting five-component markers of myocardium

Abstract

The invention relates to a biochip for detecting five-component markers of myocardium, and belongs to the technical field of POCT (Point-of-care Testing) detection. The biochip comprises a biosensor;the biosensor comprises a wafer platform and a point-like antibody coated on the wafer platform; the point-like antibody can form an immune complex with a magnetic bead-conjugated antibody and a marker protein, and the marker protein concentration can be determined by measuring the magneto resistance signal intensity on the complex on the biosensor. In the technical scheme, magnetic beads have a relatively large specific surface area, and combined with more antibodies, the detection sensitivity is improved, and the specificity is higher than that of a conventional chemiluminescence method. Theinvention further provides a detection method applicable to the biochip; by adopting the detection method, the detection range of myocardial markers is improved, cardiac markers of myocardial infarction, heart failure and pulmonary embolism can be quantitatively detected, the linear range of detection is expanded, and missing detection and false-negative phenomenon can be effectively avoided; andthe detection method is short in detection time, safe, pollution-free, and suitable for ambulance, emergency department, ICU (intensive care unit)and bedside detection.

Description

technical field [0001] The invention relates to a biochip, which is mainly used for detecting five myocardial markers in blood samples; the invention also provides a detection method using the biochip, which belongs to the technical field of POCT detection. Background technique [0002] Cardiovascular disease is a serious disease that endangers human health and life, and has become the number one killer of human health in the 21st century. According to the "China Cardiovascular Disease Report 2015" and "China Cardiovascular Disease Report 2016" compiled by the National Center for Cardiovascular Diseases, the number of patients with cardiovascular diseases in my country is still growing rapidly. According to statistics, the number of patients with cardiovascular disease was 290 million in 2014, and this number has climbed to 290 million by 2015. According to the report estimates, about 3.5 million people die of cardiovascular disease in my country every year, accounting for ...

AI Technical Summary

Problems solved by technology

[0008] The first-generation detection technology competition method (radioimmunoassay, RIA): There are many factors affected, and the RIA sample requires a large amount. Because extraction is usually required before detection, it not only increases the operation steps, but also because the recovery rate of extraction is usually Only 80% to 90%, the coefficient of variation (CV) is relatively large, which reduces the precision of detection;

[0009] The second-generation detection method non-competitive method (radioimmunoassay, RIA): immunoassay using double-antibody sandwich, no extraction, high antibody specificity, its sensitivity, precision and specificity are better than competitive methods, but time-consuming Still long and difficult to apply to automation;

[0010] The third-generation detection method enzyme immunoassay, stationary phase immunochromatography: the double antibody plus core method immunoassay solid phase chroma

Images